Ivermectin: an award-winning drug with expected antiviral activity against COVID-19

Detalhes bibliográficos
Autor(a) principal: Formiga, Fabio Rocha
Data de Publicação: 2020
Outros Autores: Leblanc, Roger, Rebouças, Juliana de Souza, Farias, Leonardo Paiva, Oliveira, Ronaldo Nascimento de, Pena, Lindomar José
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/44006
Resumo: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
id CRUZ_002a73f6b1a6e19894b4c298f1ae4cd6
oai_identifier_str oai:www.arca.fiocruz.br:icict/44006
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Formiga, Fabio RochaLeblanc, RogerRebouças, Juliana de SouzaFarias, Leonardo PaivaOliveira, Ronaldo Nascimento dePena, Lindomar José2020-10-16T14:09:45Z2020-10-16T14:09:45Z2020FORMIGA, Fabio Rocha et al. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19. Journal of Controlled Release, p. 1-5, 2020.0168-3659https://www.arca.fiocruz.br/handle/icict/4400610.1016/j.jconrel.2020.10.009Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.FACEPE (Pernambuco, Brazil), CNPq (Brazil), Inova Fiocruz (Brazil) and IDRC (Canada) for financial support. The authors also acknowledge the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001.Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Imunologia. Recife, PE, Brasil / University of Pernambuco. Graduate Program in Applied Cellular and Molecular Biology. Recife, PE, Brazil.University of Miami. Department of Chemistry. Coral Gables, FL, USA.University of Pernambuco. Institute of Biological Sciences. Recife, PE, Brazil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil.Federal Rural University of Pernambuco. Bioactive Compounds Synthesis Laboratory. Department of Chemistry. Recife, PE, Brazil.Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Virologia. Recife, PE, Brasil.Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.engElsevierIvermectinaCOVID-19SARS-CoV-2Vírus da Síndrome Respiratória Aguda GraveAntiviraisIvermectinCOVID-19SARS-CoV-2SARS virusAntiviral AgentsIvermectin: an award-winning drug with expected antiviral activity against COVID-19info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/44006/3/license.txt5a560609d32a3863062d77ff32785d58MD53ORIGINALFormiga_Fabio_etal_IGM_2020_COVID-19.pdfFormiga_Fabio_etal_IGM_2020_COVID-19.pdfapplication/pdf542528https://www.arca.fiocruz.br/bitstream/icict/44006/4/Formiga_Fabio_etal_IGM_2020_COVID-19.pdfdff7a0024d97e6d5231161db7baecd5eMD54TEXTFormiga_Fabio_etal_IGM_2020_COVID-19.pdf.txtFormiga_Fabio_etal_IGM_2020_COVID-19.pdf.txtExtracted texttext/plain32942https://www.arca.fiocruz.br/bitstream/icict/44006/5/Formiga_Fabio_etal_IGM_2020_COVID-19.pdf.txta9f590576582f7053744ccfac009f609MD55icict/440062023-03-15 14:34:24.53oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:24Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
title Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
spellingShingle Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
Formiga, Fabio Rocha
Ivermectina
COVID-19
SARS-CoV-2
Vírus da Síndrome Respiratória Aguda Grave
Antivirais
Ivermectin
COVID-19
SARS-CoV-2
SARS virus
Antiviral Agents
title_short Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
title_full Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
title_fullStr Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
title_full_unstemmed Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
title_sort Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
author Formiga, Fabio Rocha
author_facet Formiga, Fabio Rocha
Leblanc, Roger
Rebouças, Juliana de Souza
Farias, Leonardo Paiva
Oliveira, Ronaldo Nascimento de
Pena, Lindomar José
author_role author
author2 Leblanc, Roger
Rebouças, Juliana de Souza
Farias, Leonardo Paiva
Oliveira, Ronaldo Nascimento de
Pena, Lindomar José
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Formiga, Fabio Rocha
Leblanc, Roger
Rebouças, Juliana de Souza
Farias, Leonardo Paiva
Oliveira, Ronaldo Nascimento de
Pena, Lindomar José
dc.subject.other.pt_BR.fl_str_mv Ivermectina
COVID-19
SARS-CoV-2
Vírus da Síndrome Respiratória Aguda Grave
Antivirais
topic Ivermectina
COVID-19
SARS-CoV-2
Vírus da Síndrome Respiratória Aguda Grave
Antivirais
Ivermectin
COVID-19
SARS-CoV-2
SARS virus
Antiviral Agents
dc.subject.en.pt_BR.fl_str_mv Ivermectin
COVID-19
SARS-CoV-2
SARS virus
Antiviral Agents
description Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
publishDate 2020
dc.date.accessioned.fl_str_mv 2020-10-16T14:09:45Z
dc.date.available.fl_str_mv 2020-10-16T14:09:45Z
dc.date.issued.fl_str_mv 2020
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv FORMIGA, Fabio Rocha et al. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19. Journal of Controlled Release, p. 1-5, 2020.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/44006
dc.identifier.issn.pt_BR.fl_str_mv 0168-3659
dc.identifier.doi.pt_BR.fl_str_mv 10.1016/j.jconrel.2020.10.009
identifier_str_mv FORMIGA, Fabio Rocha et al. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19. Journal of Controlled Release, p. 1-5, 2020.
0168-3659
10.1016/j.jconrel.2020.10.009
url https://www.arca.fiocruz.br/handle/icict/44006
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/44006/3/license.txt
https://www.arca.fiocruz.br/bitstream/icict/44006/4/Formiga_Fabio_etal_IGM_2020_COVID-19.pdf
https://www.arca.fiocruz.br/bitstream/icict/44006/5/Formiga_Fabio_etal_IGM_2020_COVID-19.pdf.txt
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
dff7a0024d97e6d5231161db7baecd5e
a9f590576582f7053744ccfac009f609
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008875050237952

Registros relacionados